#$%^&*AU2016202918B220171130.pdf#####ABSTRACT This present invention relates to: a pharmaceutical formulation of a P2 integrin agonist including an effective amount of a P2 integrin agonist and a pharmaceutically acceptable carrier； a method of activating P2 integrins by interacting the P2 integrins with a P2 integrin agonist； a method of treating a patient by administering an effective amount of a P2 integrin agonist, and activating P2 integrins； a method of treating inflammation by administering a P2 integrin agonist to a patient with inflammation, activating P2 integrins, and reducing inflammation, or methods of treating and/or preventing renal ischemia-reperfusion (I/R) injury, reducing injury in a patient due to insertion of a stent, performing an assay for the identification of small molecule modulators of P2 integrins, detecting a disease in a patient, and improving the general wellness of a patient.
